Cboe Joins Lawsuit Challenging CFTC Approval of Perpetual Stock Derivatives
Cboe has joined a lawsuit challenging the CFTC’s approval of perpetual derivatives tied to U.S. stocks and ETFs.
Related stories
Polymarket Receives NFA Approval for PM Derivatives Futures Commission Merchant
PM Derivatives, LLC has received regulatory approval to act as a broker for customers on a fully collateralized basis.
M impact | REGULATION | Nov 03, 2026, 06:00 PM UTC
Cboe Joins Challenge to CFTC Approval of Single-Stock Perpetual Derivatives
Cboe Global Markets joined a Capital Markets Alliance challenge to CFTC approval of single-stock perpetual derivatives.
L impact | REGULATION | Nov 03, 2026, 05:38 PM UTC
Cepheid erhält FDA-Zulassung für Hämorrhagisches-Fieber-Test
Die FDA hat einen Hämorrhagisches-Fieber-Test von Cepheid, einer Tochter von Danaher, zugelassen.
M impact | REGULATION | Nov 03, 2026, 05:36 PM UTC
Danaher’s Cepheid Wins FDA Clearance for Hemorrhagic Fever Test
Danaher’s Cepheid received FDA clearance for a hemorrhagic fever test.
M impact | REGULATION | Nov 03, 2026, 05:36 PM UTC
Spain to Cut Train Frequencies and Strengthen Safety After Accident
Spain will reduce train frequencies and strengthen safety measures following an accident.
L impact | REGULATION | Nov 03, 2026, 05:35 PM UTC
Trump Says He Will Stop Sending Money to Israel
M impact | REGULATION | Nov 03, 2026, 05:24 PM UTC